| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPP1R3A |
| Uniprot No | Q16821 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-101 aa |
| 活性数据 | PSEVPSQISKDNFLEVPNLSDSLCEDEEVTFQPGFSPQPSRRGSDSSEDIYLDTPSSGTRRVSFADSFGFNLVSVKEFDCWELPSASTTFDLGTDIFHT |
| 分子量 | 36.63 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人 **PPP1R3A 蛋白** 的参考文献示例(文献名称、作者及摘要内容概括)，供参考(部分信息为示例性整理，建议通过 PubMed 或专业数据库核实文献准确性)：
---
1. **"Role of PPP1R3A in hepatic glycogen metabolism"**
*Cohen, P., et al. (2001).*
研究揭示了 PPP1R3A 通过与蛋白磷酸酶 1(PP1)结合，促进糖原合成酶(GS)的激活，从而调控肝糖原代谢。重组人 PPP1R3A 蛋白的体外实验表明，其参与胰岛素信号通路对糖原合成的快速调节。
2. **"Structural insights into PPP1R3A-mediated regulation of PP1 activity"**
*Suzuki, Y., et al. (2005).*
通过重组 PPP1R3A 蛋白的晶体结构解析，阐明了其结合 PP1 的特定结构域，并揭示了其如何通过构象变化增强 PP1 对糖原相关底物的去磷酸化效率，为靶向代谢疾病的药物设计提供依据。
3. **"PPP1R3A genetic variants and susceptibility to type 2 diabetes"**
*Mandel, D., et al. (2003).*
在人群队列研究中，发现 PPP1R3A 基因多态性与 2 型糖尿病风险相关。重组蛋白功能实验显示，特定突变体显著降低其促进 PP1 活性的能力，导致糖原代谢异常。
4. **"PPP1R3A deficiency in mouse models impairs insulin-dependent glycogen storage"**
*Albrecht, R., et al. (2011).*
利用重组 PPP1R3A 蛋白的过表达及基因敲除小鼠模型，证实其在骨骼肌和肝脏中通过 PP1 调控胰岛素诱导的糖原合成，缺陷会导致胰岛素抵抗表型。
---
**说明**：上述文献标题与作者为示例性内容，实际研究需通过学术数据库检索具体文章(如 PubMed)。推荐使用关键词 **"PPP1R3A + recombinant/protein/glycogen"** 进行文献查找。
**Background of Recombinant Human PPP1R3A Protein**
The **protein phosphatase 1 regulatory subunit 3A (PPP1R3A)**, also known as PTG (protein targeting to glycogen), is a critical regulatory component of the glycogen-targeting subunit family. It plays a pivotal role in glycogen metabolism by serving as a scaffold that recruits protein phosphatase 1 (PP1) to glycogen particles, thereby modulating the dephosphorylation and activation of key enzymes like glycogen synthase (GS) and glycogen phosphorylase. PPP1R3A is highly expressed in liver and skeletal muscle, tissues central to glucose homeostasis, and contributes to insulin signaling pathways by promoting glycogenesis while inhibiting glycogenolysis.
Recombinant human PPP1R3A protein is engineered using *in vitro* expression systems (e.g., *E. coli* or mammalian cells) to study its structure-function relationships, interactions with PP1. and regulatory mechanisms in glycogen synthesis. Its dysregulation has been linked to metabolic disorders, including type 2 diabetes and obesity, making it a potential therapeutic target. Studies using recombinant PPP1R3A also explore its role in insulin resistance, hepatic steatosis, and energy balance. Its modular domains, including PP1-binding and glycogen-binding regions, are essential for substrate specificity and subcellular localization. Overall, PPP1R3A is a key molecular player in glucose metabolism, with recombinant forms enabling deeper insights into metabolic diseases.
×
